Results 101 to 110 of about 24,420 (229)

AT1 receptor downregulation: A mechanism for improving glucose homeostasis. [PDF]

World J Diabetes, 2023
Lopez DL, Casillas OE, Jaramillo HJ, Romero-Garcia T, Vazquez-Jimenez JG.   +4 more
europepmc   +1 more source

The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Statins, widely prescribed for cardiovascular prevention, have emerged as potential disease‐modifying agents in neurodegenerative disorders due to their pleiotropic effects on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation.
Luigi Maria Chiatto, Lucia Buccarello, Giuseppe Carota, Rocco Salvatore Calabrò, Carmela Rifici, Emanuela Esposito, Alessio Ardizzone, Giuseppe Caruso   +7 more
wiley   +1 more source

Distinctions between non-peptide angiotensin II AT1-receptor antagonists

, 2001
A far-reaching understanding of the molecular action mechanism of AT1-receptor antagonists (AIIAs) was obtained by using CHO cells expressing transfected human AT 1-receptors.
Ilse Verheijen, Frederik LP Fierens, Georges Vauquelin, Patrick ML Vanderheyden   +3 more
core   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, Volume 183, Issue 12, Page 3377-3394, June 2026.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

Journal of Neuroinflammation, 2012
Background Several recent studies have shown that angiotensin type 1 receptor (AT1) antagonists such as candesartan inhibit the microglial inflammatory response and dopaminergic cell loss in animal models of Parkinson's disease.
Garrido-Gil Pablo, Joglar Belen, Rodriguez-Perez Ana I, Guerra Maria J, Labandeira-Garcia Jose L   +4 more
doaj   +1 more source

Effect of AT1 receptor blockade on cardiovascular outcome after cardiac arrest: an experimental study in rats. [PDF]

Sci Rep, 2023
Araújo Filho EAF, Carmona MJC, Otsuki DA, Maia DRR, Lima LGCA, Vane MF.   +5 more
europepmc   +1 more source

GRKs and arrestins: Nomenclature and functions in GPCR‐dependent and ‐independent signalling

British Journal of Pharmacology, Volume 183, Issue 11, Page 2619-2633, June 2026.
G protein‐coupled receptor (GPCR) kinases (GRKs) and arrestins play a critical role in the regulation of GPCR signalling. Historic names of mammalian GRKs were replaced by systematic ones in the 1990s; however, both kinds of names are currently in use for mammalian arrestins.
Vsevolod V. Gurevich
wiley   +1 more source

Characterization of the First Animal Toxin Acting as an Antagonist on AT1 Receptor. [PDF]

Int J Mol Sci, 2023
Van Baelen AC, Iturrioz X, Chaigneau M, Kessler P, Llorens-Cortes C, Servent D, Gilles N, Robin P.   +7 more
europepmc   +1 more source

Síntese de potenciais antagonistas do receptor b1 da bradicinina contendo o heterociclo dihidropiridazinona [PDF]

, 2010
TCC (graduação) - Universidade Federal de Santa Catarina, Centro de Ciências Físicas e Matemáticas, Curso de Química.Com base nas estruturas de seletivos antagonistas não peptídicos do receptor B1 da bradicinina, foram desenvolvidos novos análogos ...
Maximiano, Adrielle Patricio
core  

A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor

, 2011
Heterodimerization of the angiotensin II AT1 receptor with the receptor for the vasodepressor bradykinin, B2R, is known to sensitize the AT1-stimulated response of hypertensive individuals in vivo.
Ursula Quitterer, Quitterer, U, Langer, A, Langer, Andreas, Abdalla, S, Armin Pohl, Pohl, A, Quitterer, Ursula, Koller, S, Koller, Samuel, Andreas Langer, Pohl, Armin, Samuel Koller, AbdAlla, Said, Said AbdAlla   +14 more
core   +1 more source